Connectivity is what separates networked glucose testing from conventional meters, and it is shaping how the Network Point-Of-Care Glucose Testing market evolves. Polaris Market Research values the industry at USD 1,387.65 million in 2024 and USD 1,443.85 million in 2025, with a projection of USD 2,109.01 million by 2034 at a CAGR of 4.3%. The report segments the market by product, modality and region.

Portability Powers Growth

Within modality, handheld/portable devices are experiencing the highest growth rate. Their portability and ease of use suit point-of-care settings, allowing rapid glucose assessments in diverse environments, including remote and underserved areas. Demand for immediate and accurate measurements, together with advances in connectivity and integration with broader healthcare systems, has fueled the segment's expansion, and adoption is expected to rise as healthcare systems continue to prioritize accessibility and efficiency. Benchtop devices complete the modality segmentation.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/network-point-of-care-glucose-testing-market

Connected Products Raising the Bar

The product segmentation also includes HemoCue, BAROzen H Expert Plus and i-STAT. CareSens Expert Plus is anticipated to experience the highest growth rate among products, based on advanced features such as automatic strip recognition for both glucose and β-ketones and real-time data transfer through Wi-Fi, Ethernet, USB and NFC. These capabilities enhance user experience and facilitate integration with the wider healthcare environment, making the device a preferred choice in settings that prioritize advanced data management and connectivity.

Wireless Adoption in Regional Context

The adoption of wireless and cloud-based technologies is a key trend, enabling remote monitoring and streamlined data management. Regulatory support for point-of-care testing and growing investments in healthcare infrastructure are also contributing to growth. Europe is seeing substantial expansion supported by government initiatives to enhance diabetes care and the widespread adoption of advanced glucose monitoring technologies. In Asia Pacific, the rising incidence of diabetes in China and India, higher healthcare expenditure, greater awareness of early disease detection and improved access to point-of-care testing devices are fueling expansion.

Security, Interoperability and Competitive Response

Data security and interoperability issues are identified as a restraint, alongside high device costs. In March 2024, Nova Biomedical introduced its next-generation StatStrip Glucose Hospital Meter System, which received FDA 510(k) clearance. The updated meter includes improved cybersecurity, wireless charging, RFID data entry and a durable casing, supporting precise and secure glucose testing for critically ill patients. More broadly, companies are expanding portfolios through technological advancement, pursuing strategic collaborations with healthcare providers and digital health platforms, and relying on regulatory approvals and compliance with healthcare standards to drive adoption in hospitals and home care settings.

Where New Entrants Can Compete

For companies looking to enter the market, the report points to several areas of focus, including noninvasive glucose testing, AI-driven predictive analytics and cloud-based remote monitoring solutions. Partnering with healthcare providers and insurers can improve accessibility and reimbursement options, while affordable, portable and user-friendly devices can help capture underserved populations in emerging markets. Ensuring regulatory compliance and meeting high security standards are described as critical for market acceptance and long-term success.

Key Players in the Network Point-Of-Care Glucose Testing Market

Abbott, Roche, Nova Biomedical, Ascensia and LifeScan are among the companies advancing diabetes management solutions. Key players include:

•       ACON Laboratories, Inc.

•       Abbott Laboratories

•       ARKRAY, Inc.

•       Ascensia Diabetes Care Holdings AG

•       Danaher Corporation (HemoCue subsidiary)

•       DexCom, Inc.

•       EKF Diagnostics Holdings plc.

•       F. Hoffmann-La Roche Ltd.

•       LifeScan, Inc. (Platinum Equity Advisors, LLC subsidiary)

•       Medtronic plc

•       Nipro Corporation Japan

•       Nova Biomedical Corporation

•       Prodigy Diabetes Care, LLC

•       Terumo Corporation

•       Trividia Health, Inc.

Conclusion

Portability, richer connectivity and stronger security safeguards are the factors to watch as the Network Point-Of-Care Glucose Testing market expands to USD 2,109.01 million by 2034. As healthcare systems prioritize accessibility and efficiency, vendors that deliver dependable devices alongside secure data exchange can strengthen their standing across North America, Europe and Asia Pacific.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market